- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05660122
A Study to Evaluate the Improvement Effect on Subjective Symptom of FEXUCLUE Tab
A Multi-Center, Prospective, Observational Study to Evaluate the Improvement Effect on Subjective Symptom of FEXUCLUE Tab. in Patients With Erosive Gastroesophageal Reflux Disease
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This observation study is a large-scale, prospective, and multi-organ observation study to observe the improvement effect of the self-evaluation results (PRO) of erosive gastroesophageal reflux disease at least 4 to 8 weeks after administration of Fexuclue Tab.
Subjects who met the inclusion/exclusion criteria will administer Fexuclue Tablet once a day for four weeks after registration, regardless of their meals. If esophagitis is not treated or symptoms continue after 4 weeks of administration, the subject will continue to administer Fexuclue Tablet for 4 more weeks (maximum administration period: 8 weeks).
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: HyeongSeon Noh
- Phone Number: 8210-4266-0549
- Email: hsno116@daewoong.co.kr
Study Locations
-
-
-
Busan, Korea, Republic of
- Recruiting
- Kosin University Gospel Hospital
-
Contact:
- KiEun Kwon
- Phone Number: 051-990-6771
- Email: kosinirb@kosinmed.or.kr
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
This observation research plan assumes the following.
- level of signification, α=0.05
- Distance from Mean to Limits = 0.067
- Standard deviation of the amount of change at the time of two weeks compared to the baseline of the RDQ score = 1.66
As a result of calculating using PASS2020 based on the above assumptions, the number of study subjects required to conduct this study was 2,359. In consideration of the dropout rate of about 20% in the calculated results, we intend to recruit 3,000 study subjects.
Description
Inclusion Criteria:
- Adult men and women aged 19 to 75 years of age at the time of registration.
- A patient with erosive gastroesophageal reflux disease who is scheduled to administer Fexuclue Tab. for the first time based on the medical judgement of the researcher based on the medication authorization.
- A person who voluntarily agrees to participate in this observation study and signed the informed consent form.
Exclusion Criteria:
A person who falls under the prohibition of administration according to the permission for Fexuclue Tablet
- Patients with hypersensitivity to the components of Fexuclue tablet or Fexuclue tablet and a history thereof
- Patients undergoing Atazanavir, Nelfinavir or Lilpivirin-containing preparations
- Pregnant and lactating women
- Patients with genetic problems such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabortion
- A person who participates in another clinical trial and is administering (applying) clinical trial drugs or clinical trial medical devices;
- In addition to the above, a person who has determined that the researcher (the doctor in charge) is not suitable for participation in this observation study
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Only
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Treatment group
patients with gastroesophageal reflux disease
|
Fexuclue Tablet 40mg
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Average score change
Time Frame: at 4 weeks (up to 8 weeks)
|
in Reflux Disease Questionnaire
|
at 4 weeks (up to 8 weeks)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Average score change
Time Frame: at 4 weeks (up to 8 weeks)
|
individual score in Reflux Disease Questionnaire
|
at 4 weeks (up to 8 weeks)
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- DWFE_P405
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Gastroesophageal Reflux Disease
-
TakedaTerminatedGastroesophageal Reflux Disease | Non-erosive Reflux DiseaseSwitzerland, Netherlands
-
Vanderbilt University Medical CenterCompletedGastroesophageal Reflux Disease (GERD) | Non-erosive Reflux Disease (NERD)United States
-
Mansoura UniversityWithdrawnGastroesophageal Reflux Disease
-
Cliniques universitaires Saint-Luc- Université...UnknownGastroesophageal Reflux DiseaseBelgium
-
GlaxoSmithKlineCompletedReflux, Gastroesophageal | Gastroesophageal Reflux DiseaseAustralia
-
King Chulalongkorn Memorial HospitalCompleted
-
University of North Carolina, Chapel HillNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedGastroesophageal Reflux Disease | GERD | Acid Reflux | RefluxUnited States
-
PfizerTerminatedGastroesophageal Reflux DiseaseBrazil, Germany, Korea, Republic of, Belgium, Spain, Slovakia, France
-
GlaxoSmithKlineCompletedReflux, Gastroesophageal | Gastroesophageal Reflux DiseaseAustralia
-
Duke UniversityNational Heart, Lung, and Blood Institute (NHLBI)CompletedGastroesophageal Reflux Disease (GERD) | RefluxUnited States, Canada
Clinical Trials on Fexuprazan Hydrochloride
-
Daewoong Pharmaceutical Co. LTD.RecruitingGastroesophageal Reflux DiseaseKorea, Republic of
-
Daewoong Pharmaceutical Co. LTD.RecruitingGastroesophageal Reflux DiseaseKorea, Republic of
-
Yonsei UniversityNot yet recruitingPatients on Treatment With Systemic SteroidsKorea, Republic of
-
Daewoong Pharmaceutical Co. LTD.RecruitingNon-erosive Reflux Disease | Non-Erosive Gastro-Esophageal Reflux Disease | Non-Erosive Esophageal Reflux DiseaseKorea, Republic of
-
Daewoong Pharmaceutical Co. LTD.Shanghai Haini Pharmaceutical Co., Ltd.Active, not recruitingPhase 1 Study, Healthy VolunteersChina
-
Xijing Hospital of Digestive DiseasesCompletedColorectal AdenomasChina
-
Shenyang Sunshine Pharmaceutical Co., LTD.UnknownUremic PruritusChina
-
Xijing Hospital of Digestive DiseasesCompleted
-
M.D. Anderson Cancer CenterWithdrawnMetastatic Lung Non-Small Cell Carcinoma | Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8
-
Betta Pharmaceuticals Co., Ltd.Tigermed Consulting Co., LtdCompleted